Your browser doesn't support javascript.
loading
Component-resolved diagnosis and beyond: Multivariable regression models to predict severity of hazelnut allergy.
Datema, M R; van Ree, R; Asero, R; Barreales, L; Belohlavkova, S; de Blay, F; Clausen, M; Dubakiene, R; Fernández-Perez, C; Fritsche, P; Gislason, D; Hoffmann-Sommergruber, K; Jedrzejczak-Czechowicz, M; Jongejan, L; Knulst, A C; Kowalski, M; Kralimarkova, T Z; Le, T-M; Lidholm, J; Papadopoulos, N G; Popov, T A; Del Prado, N; Purohit, A; Reig, I; Seneviratne, S L; Sinaniotis, A; Versteeg, S A; Vieths, S; Zwinderman, A H; Mills, E N C; Fernández-Rivas, M; Ballmer-Weber, B.
Afiliação
  • Datema MR; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
  • van Ree R; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
  • Asero R; Department of Otorhinolaryngology, Academic Medical Center, Amsterdam, The Netherlands.
  • Barreales L; Ambulatorio di Allergologia, Clinica San Carlo, Paderno Dugnano, Italy.
  • Belohlavkova S; Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • de Blay F; Medical Faculty Pilsen, Charles University Prague.
  • Clausen M; Allergy Division, Chest Disease Department, Strasbourg University Hospital, Strasbourg, France.
  • Dubakiene R; Faculty of Medicine, University of Iceland, Landspitali University Hospital, Reykjavik, Iceland.
  • Fernández-Perez C; Medical Faculty, Vilnius University, Vilnius, Lithuania.
  • Fritsche P; Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • Gislason D; Allergy Unit, Department of Dermatology, University Hospital Zürich, Zürich, Switzerland.
  • Hoffmann-Sommergruber K; Faculty of Medicine, University of Iceland, Landspitali University Hospital, Reykjavik, Iceland.
  • Jedrzejczak-Czechowicz M; Department of Pathophysiology and Allergy Research, Medical University of Vienna, Vienna, Austria.
  • Jongejan L; Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
  • Knulst AC; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
  • Kowalski M; Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Kralimarkova TZ; Department of Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
  • Le TM; Clinic of Allergy and Asthma, Medical University of Sofia, Sofia, Bulgaria.
  • Lidholm J; Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Papadopoulos NG; Thermo Fisher Scientific, Uppsala, Sweden.
  • Popov TA; Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
  • Del Prado N; Centre for Paediatrics and Child Health, Institute of Human Development, University of Manchester, Manchester, UK.
  • Purohit A; Clinic of Allergy and Asthma, Medical University of Sofia, Sofia, Bulgaria.
  • Reig I; Clinical epidemiology Unit, Preventive Medicine Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • Seneviratne SL; Allergy Division, Chest Disease Department, Strasbourg University Hospital, Strasbourg, France.
  • Sinaniotis A; Allergy Department, Hospital Clinico San Carlos, IdISSC, Madrid, Spain.
  • Versteeg SA; Institute of Immunity and Transplantation, University College London, London, UK.
  • Vieths S; Allergy Department, 2nd Pediatric Clinic, University of Athens, Athens, Greece.
  • Zwinderman AH; Department of Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands.
  • Mills ENC; Division of Allergology, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Fernández-Rivas M; Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Center, Amsterdam, The Netherlands.
  • Ballmer-Weber B; Institute of Inflammation and Repair, Manchester Academic Health Science Centre, Manchester Institute of Biotechnology, The University of Manchester, Manchester, UK.
Allergy ; 73(3): 549-559, 2018 03.
Article em En | MEDLINE | ID: mdl-28986984
ABSTRACT

BACKGROUND:

Component-resolved diagnosis (CRD) has revealed significant associations between IgE against individual allergens and severity of hazelnut allergy. Less attention has been given to combining them with clinical factors in predicting severity.

AIM:

To analyze associations between severity and sensitization patterns, patient characteristics and clinical history, and to develop models to improve predictive accuracy.

METHODS:

Patients reporting hazelnut allergy (n = 423) from 12 European cities were tested for IgE against individual hazelnut allergens. Symptoms (reported and during Double-blind placebo-controlled food challenge [DBPCFC]) were categorized in mild, moderate, and severe. Multiple regression models to predict severity were generated from clinical factors and sensitization patterns (CRD- and extract-based). Odds ratios (ORs) and areas under receiver-operating characteristic (ROC) curves (AUCs) were used to evaluate their predictive value.

RESULTS:

Cor a 9 and 14 were positively (OR 10.5 and 10.1, respectively), and Cor a 1 negatively (OR 0.14) associated with severe symptoms during DBPCFC, with AUCs of 0.70-073. Combining Cor a 1 and 9 improved this to 0.76. A model using a combination of atopic dermatitis (risk), pollen allergy (protection), IgE against Cor a 14 (risk) and walnut (risk) increased the AUC to 0.91. At 92% sensitivity, the specificity was 76.3%, and the positive and negative predictive values 62.2% and 95.7%, respectively. For reported symptoms, associations and generated models proved to be almost identical but weaker.

CONCLUSION:

A model combining CRD with clinical background and extract-based serology is superior to CRD alone in assessing the risk of severe reactions to hazelnut, particular in ruling out severe reactions.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersensibilidade a Noz / Corylus Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Allergy Ano de publicação: 2018 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipersensibilidade a Noz / Corylus Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Allergy Ano de publicação: 2018 Tipo de documento: Article